FDA DEVICE FACTS
Blue Non Sterile Powder Free Nitrile Examination Gloves, Tested for Use with Chemotherapy Drugs, with Gastric Acid and Fentanyl Permeation Resistance Claims.
Central Medicare Sdn Bhd
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
Blue Non Sterile Powder Free Nitrile Examination Gloves, Tested for Use with Chemotherapy Drugs, with Gastric Acid and Fentanyl Permeation Resistance Claims is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. Tested for Use with Chemotherapy Drugs - Gloves have been tested for use with chemotherapy drugs using ASTM D6978-05 and will be labeled with a statement of compliance and a summary of the testing results. Tested chemotherapy drugs and average breakthrough detection time (minutes) are as follows: Arsenic Trioxide 1.0 mg/ml >240 mins Azacitidine (Vidaza) 25.0 mg/ml > 240 mins Bendamustine HCI 5.0 mg/ml > 240 mins Bleomycin Sulfate 15.0 mg/ml > 240 mins Busulfan 6.0 mg/ml > 240 mins Carboplatin 10.0 mg/ml > 240 mins Carmustine (BCNU) 3.3 mg/ml 12.7 mins Carfilzomib 2.0 mg/ml > 240 mins Cetuximab 2.0 mg/ml > 240 mins Chloroquine 50.0 mg/ml > 240 mins Cisplatin 1.0 mg/ml > 240 mins Cladribine 1.0 mg/ml > 240 mins Cyclophosphamide (Cytoxan) 20.0 mg/ml > 240 mins Cyclosporin A 100.0 mg/ml > 240 mins Cytarabine 100.0 mg/ml > 240 mins Cytovene (Ganciclovir) 10.0 mg/ml > 240 mins Dacarbazine 10.0 mg/ml > 240 mins Daunorubicin 5.0 mg/ml > 240 mins Decitibine 5.0 mg/ml > 240 mins Docetaxel 10.0 mg/ml > 240 mins Doxorubicin Hydrochloride 2.0 mg/ml > 240 mins Epirubicin (Ellence) 2.0 mg/ml > 240 mins Etoposide (Toposar) 20.0 mg/ml > 240 mins Fludarabine 25.0 mg/ml > 240 mins Fluorouracil 50.0 mg/ml > 240 mins Fulvestrant 50.0 mg/ml > 240 mins Gemcitabine (Gemzar) 38.0 mg/ml > 240 mins Idarubicin 1.0 mg/ml > 240 mins Ifosfamide 50.0 mg/ml > 240 mins Irinotecan 20.0 mg/ml > 240 mins Mechlorethamine HCI 1.0 mg/ml > 240 mins Melphalan 5.0 mg/ml > 240 mins Mesna 50.0 mg/ml >240 mins Methotrexate 25.0 mg/ml > 240 mins Mitomycin C 0.5 mg/ml > 240 mins Mitoxantrone 2.0 mg/ml > 240 mins Oxaliplatin 2.0 mg/ml > 240 mins Paclitaxel 6.0 mg/ml > 240 mins Paraplatin 10.0 mg/ml > 240 mins Pemetrexed 25.0 mg/ml > 240 mins Pertuzumab 30.0 mg/ml >240 mins Propofol 10.0 mg/ml > 240 mins Raltitrexed 0.5 mg/ml > 240 mins Retrovir 10.0 mg/ml > 240 mins Rituximab 10.0 mg/ml > 240 mins Temsirolimus 25.0 mg/ml >240 mins Thiotepa 10 mg/ml 35.8 mins Topotecan HCI 1.0 mg/ml > 240 mins Trastuzumab 21.0 mg/ml >240 mins Triclosan 2.0 mg/ml > 240 mins Trisenox (Arsenic Trioxide) 1.0 mg/ml > 240 mins Velcade (Bortezomib) 1.0 mg/ml > 240 mins Vinblastine 1.0 mg/ml > 240 mins Vincristine Sulfate 1.0 mg/ml > 240 mins Vinorelbine 10.0 mg/ml > 240 mins Zoledronic Acid 0.8 mg/ml > 240 mins CAUTION: Testing showed an average breakthrough time of 35.8 minutes with Thiotepa and 12.7 minutes with Carmustine. WARNING: Do not use with Carmustine and Thiotepa. Fentanyl Permeation Resistance Claim - Under the testing conditions of ASTM D6978-05, Fentanyl Citrate Injection (100mcg/2mL) was found to have no breakthrough detected up to 240 minutes. Gastric Acid Permeation Resistance Claim - Under the testing conditions of ASTM D6978-05, was found to have no breakthrough detected up to 240 minutes.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。